Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNOUNCE: Olaratumab + Doxorubicin in Advanced Soft Tissue Sarcoma
NCT02451943Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Doxorubicin + Olaratumab with Doxorubicin + Placebo (2 arms). Primary endpoints: Overall Survival up to 35.8 Months and Overall Survival in Leiomyosarcoma Population up to 35.8 Months. Started Sep 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02451943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451943.